SCHEMBL6711615

SCHEMBL6711615

CN(/N=C\c1ccccn1)c1ccccn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.56
G6PC1 P35575 1/20 0.51
MAOA P21397 2/20 0.50
MAOB P27338 1/20 0.50
NR4A1 P22736 1/20 0.49
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
ATM Q13315 1/20 0.45
ALDH1A1 P00352 1/20 0.44
PKM P14618 1/20 0.44
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
TOP2A P11388 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
KDM4E B2RXH2 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 1/20 0.41
CTH P32929 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6711619 1.00 USP2 (0.56) USP2G6PC1MAOAMAOBNR4A1
SCHEMBL28295586 0.83 SMN1; SMN2 (0.51) USP2G6PC1NPC1RAB9AMEN1
SCHEMBL3943697 0.83 USP2 (0.70) USP2G6PC1MAOAMAOBNR4A1
SCHEMBL3943694 0.83 USP2 (0.70) USP2G6PC1MAOAMAOBNR4A1
SCHEMBL14517008 0.82 USP2 (0.62) USP2G6PC1MAOAMAOBNR4A1
SCHEMBL22862043 0.82 USP2 (0.62) USP2G6PC1MAOAMAOBNR4A1
SCHEMBL24724667 0.80 CYP2D6 (0.46) USP2MAOAMAOBNPC1RAB9A
SCHEMBL10902892 0.78 CYP1A2 (0.41) USP2MAOAMAOBNPC1RAB9A
SCHEMBL9768784 0.73 USP2 (0.57) USP2G6PC1MAOAMAOBNR4A1
SCHEMBL9768782 0.73 USP2 (0.57) USP2G6PC1MAOAMAOBNR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040053977-A1 Medicinal uses of hydrazones ALMSTEAD JI-IN KIM (US) 2004-03-18 US claimed
US-6660737-B2 Antihypoxic agents THE PROCTER & GAMBLE COMPANY 2003-12-09 US claimed
US-20030092716-A1 Medicinal uses of hydrazones THE PROCTER & GAMBLE COMPANY 2003-05-15 US claimed
US-20040053977-A1 Medicinal uses of hydrazones ALMSTEAD JI-IN KIM (US) 2004-03-18 US disclosed
US-6660737-B2 Antihypoxic agents THE PROCTER & GAMBLE COMPANY 2003-12-09 US disclosed
US-20030092716-A1 Medicinal uses of hydrazones THE PROCTER & GAMBLE COMPANY 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053977-A1 Medicinal uses of hydrazones PGF, VEGFA, TEK USP2 3452/4885G6PC1 1699/4885MAOA 1156/4885
US-20030092716-A1 Medicinal uses of hydrazones EPOR, VEGFA, HIF1A USP2 3725/4885G6PC1 1336/4885MAOA 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.